Revolutionizing IBS Management with Real-World Data
Biomerica, Inc. (NASDAQ: BMRA), a leading innovator in diagnostic-guided therapies, has unveiled groundbreaking real-world results showcasing the effectiveness of inFoods® IBS. This product, combined with an advanced real-time patient feedback system, can significantly enhance symptom management for those suffering from Irritable Bowel Syndrome (IBS).
Remarkable Reductions in Symptoms
Recent data compiled from over 360 patients reveals impressive results: participants reported an average reduction of 48.5% in gastrointestinal (GI) pain and a 49.8% drop in bloating over an eight-week treatment period. This ongoing study highlights the importance of patient feedback in managing IBS symptoms.
A Closer Look at Patient Outcomes
The inFoods® IBS study is structured to track symptom reduction beginning with a two-week baseline, followed by an eight-week intervention phase where patients eliminate food triggers specific to their condition. This method has shown comparable, if not superior, results compared to previous clinical trials across leading American medical centers.
“It’s gratifying to present this compelling data that illustrates the benefits our inFoods® IBS system offers to patients dealing with this challenging condition,” stated Zack Irani, CEO of Biomerica. “The feedback system we’ve developed allows physicians to maintain insight into patient progress, evolving treatment on a personalized basis, which is key to effective IBS management.”
Enhancing Clinical Decision-Making
The innovative feedback platform developed by Biomerica adheres to HIPAA regulations, thereby ensuring patient privacy while providing healthcare professionals with timely, actionable insights. Clinicians can now adjust treatment plans dynamically based on real-time patient-reported outcomes, improving the overall quality of care offered to those with IBS.
Scientific Backing for a Transformative Approach
This promising real-world information is substantiated by a peer-reviewed study published in the journal Gastroenterology, which illustrated that patients following a diet guided by inFoods® IBS experienced a higher rate of abdominal pain relief compared to those adhering to a placebo diet. The findings underscore the potential of inFoods® IBS as a viable treatment option.
Tackling a Significant Healthcare Challenge
IBS impacts an estimated 10% to 15% of adults, causing considerable disruption to daily life, decreased productivity, and a dependency on medications that often come with undesirable side effects. The inFoods® IBS system offers a cutting-edge, non-pharmaceutical approach by identifying food triggers, helping both patients and clinicians focus on dietary changes that can alleviate symptoms effectively.
By utilizing a diagnostic-guided methodology, Biomerica’s inFoods® IBS not only provides a personalized approach to IBS treatment but also stands out for its affordability, making it accessible for many patients seeking relief from their gastrointestinal struggles.
About Biomerica and its Commitment to Healthcare Innovation
Biomerica, Inc. (NASDAQ: BMRA) specializes in developing, patenting, manufacturing, and marketing advanced diagnostic and therapeutic products aimed at improving health outcomes. Their efforts are directed primarily towards gastrointestinal and inflammatory diseases, with multiple diagnostic and therapeutic solutions under development.
The inFoods® IBS assessment has been designed to evaluate an individual’s immune response to specific food items through a simple blood test. It allows healthcare providers to tailor dietary recommendations that target specific triggers, leading to the potential alleviation of IBS-related symptoms.
With firm backing from prestigious institutions such as Mayo Clinic and the University of Michigan, the inFoods® IBS test aims not only to be clinically effective but also to significantly enhance the quality of life for individuals grappling with IBS. This patient-centric model serves a growing demand for more precise healthcare solutions.
Corporate Contact Information
Zack Irani
949-645-2111
investors@biomerica.com
Frequently Asked Questions
What is inFoods® IBS?
inFoods® IBS is a diagnostic-guided therapy that helps identify individual food triggers that exacerbate IBS symptoms.
How does the real-time feedback system work?
The feedback system allows physicians to receive continuous updates on patient-reported outcomes to make timely treatment adjustments.
What are the key benefits of using inFoods® IBS?
This system has significantly reduced GI pain and bloating in patients, offering a personalized, non-drug treatment option.
Who conducted the associated studies?
Leading institutions like the Cleveland Clinic and the University of Michigan participated in clinical trials to validate the efficacy of inFoods® IBS.
How can I learn more about Biomerica and its products?
More information is available at Biomerica's website, which outlines their products and innovative healthcare solutions.
